Literature DB >> 23512234

Does dental and oral health influence the development and course of bisphosphonate-related osteonecrosis of the jaws (BRONJ)?

Michael Krimmel1, Jana Ripperger, Martin Hairass, Sebastian Hoefert, Susanne Kluba, Siegmar Reinert.   

Abstract

PURPOSE: The main causes for the occurrence of bisphosphonate-related osteonecrosis of the jaws (BRONJ) are the application of aminobisphosphonates and the extraction of teeth. However, the question which factors in dental and oral health are relevant has not been answered completely.
MATERIALS AND METHODS: In a retrospective study, 50 patients who were treated with BRONJ between 2000 and 2009 were analyzed. As underlying diseases, they suffered from breast cancer (n = 24), multiple myeloma (n = 16), prostate cancer (n = 5), osteoporosis (n = 4), and kidney cancer (n = 1). The data were collected from the patient charts of the treating dentists, oral and maxillofacial surgeons, general practitioners, and oncologists. The time of occurrence of BRONJ after treatment onset with bisphosphonates (BP) was examined with Kaplan-Meier estimator and logrank test (level of significance 0.05).
RESULTS: At the time of BP treatment, onset the decayed, missing, and filled teeth (DMFT) index was 20.5 ± 4.2. Patients with a DMFT value less than 20 showed a significantly longer BRONJ-free time interval after BP treatment onset with 39.7 ± 1.1 months compared to patients with a DMFT value higher than 20, in whom BRONJ appeared after 14.4 ± 2.8 months (p < 0.001). However, the DMFT value had no influence on the success rate of BRONJ treatment. As a pre-existing oral disease, 60 % of the patients (n = 30) had marginal periodontitis; 38 % (n = 19), apical periodontitis; and 22 % (n = 11), a pressure lesion from their dentures. In patients with marginal periodontitis, BRONJ occurred after 26.3 months (range 20.9-31.3) and in patients without marginal periodontitis, after 27.4 months (range 14.6-40.1) (p = 0.58). Only 20 % of the patients with marginal periodontitis received adequate treatment. Without parodontal treatment, BRONJ occurred 15 months earlier compared to patients with parodontal treatment (p = 0.12). The state of the periodontium did not influence the healing rate of BRONJ (p > 0.999).
CONCLUSION: The present study highlights the great benefit of good dental and oral health in the prevention of BRONJ; but it also shows that after the appearance of BRONJ, these factors do no longer seem to play a relevant role in the disease course.

Entities:  

Mesh:

Year:  2013        PMID: 23512234     DOI: 10.1007/s10006-013-0408-3

Source DB:  PubMed          Journal:  Oral Maxillofac Surg        ISSN: 1865-1550


  18 in total

1.  Osteonecrosis of the jaw and bisphosphonates.

Authors:  Brian G M Durie; Michael Katz; John Crowley
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

2.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws.

Authors: 
Journal:  J Oral Maxillofac Surg       Date:  2007-03       Impact factor: 1.895

3.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; Leon A Assael; Regina Landesberg; Robert E Marx; Bhoomi Mehrotra
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

Review 4.  [Bisphosphonate-associated osteonecrosis of the jaw].

Authors:  M H Abu-Id; Y Açil; J Gottschalk; T Kreusch
Journal:  Mund Kiefer Gesichtschir       Date:  2006-03

Review 5.  Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.

Authors:  Sook-Bin Woo; John W Hellstein; John R Kalmar
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

6.  Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

Authors:  Ashraf Badros; Dianna Weikel; Andrew Salama; Olga Goloubeva; Abraham Schneider; Aaron Rapoport; Robert Fenton; Natalie Gahres; Edward Sausville; Robert Ord; Timothy Meiller
Journal:  J Clin Oncol       Date:  2006-02-20       Impact factor: 44.544

7.  Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.

Authors:  T Fehm; V Beck; M Banys; H P Lipp; M Hairass; S Reinert; E F Solomayer; D Wallwiener; M Krimmel
Journal:  Gynecol Oncol       Date:  2009-01-12       Impact factor: 5.482

8.  Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

Authors:  C I Ripamonti; M Maniezzo; T Campa; E Fagnoni; C Brunelli; G Saibene; C Bareggi; L Ascani; E Cislaghi
Journal:  Ann Oncol       Date:  2008-07-22       Impact factor: 32.976

9.  A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.

Authors:  A Corso; M Varettoni; P Zappasodi; C Klersy; S Mangiacavalli; G Pica; M Lazzarino
Journal:  Leukemia       Date:  2007-04-05       Impact factor: 11.528

10.  Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.

Authors:  Ana O Hoff; Béla B Toth; Kadri Altundag; Marcella M Johnson; Carla L Warneke; Mimi Hu; Ajay Nooka; Gilbert Sayegh; Valentina Guarneri; Kimberly Desrouleaux; Jeffrey Cui; Andrea Adamus; Robert F Gagel; Gabriel N Hortobagyi
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741

View more
  11 in total

1.  Zoledronate induces bisphosphonate-related osteonecrosis of the jaw in osteopenic sheep.

Authors:  Pit J Voss; Martin J Stoddart; Anke Bernstein; Rainer Schmelzeisen; Katja Nelson; Vincent Stadelmann; Thomas Ziebart; Philipp J Poxleitner
Journal:  Clin Oral Investig       Date:  2015-04-07       Impact factor: 3.573

2.  Influence of the cumulative effect of zoledronic acid on periodontal microcirculation in rats.

Authors:  G A Kosach; A L Petrosyan; A I Yaremenko; S I Kutukova; A A Zubareva; S G Chefu; T D Vlasov
Journal:  Oral Maxillofac Surg       Date:  2021-02-14

3.  The association between the severity of periodontitis and osteonecrosis of the jaw in patients with different cancer locations: a nationwide population-based study.

Authors:  Yi-Fang Huang; Kuan-Chou Lin; Shih-Ping Liu; Chung-Ta Chang; Chih-Hsin Muo; Po-Jen Chang; Chun-Hao Tsai; Ching-Zong Wu
Journal:  Clin Oral Investig       Date:  2022-04-28       Impact factor: 3.573

Review 4.  Detecting the earliest radiological signs of bisphosphonate-related osteonecrosis.

Authors:  H Devlin; J Greenwall-Cohen; J Benton; T L Goodwin; A Littlewood; K Horner
Journal:  Br Dent J       Date:  2017-11-17       Impact factor: 1.626

5.  Oral health condition in cancer patients under bisphosphonate therapy.

Authors:  Rogério Jardim Caldas; Héliton Spíndola Antunes; Camila de Oliveira Rodini Pegoraro; Fábio Ribeiro Guedes; Paulo Sérgio da Silva Santos
Journal:  Support Care Cancer       Date:  2021-06-18       Impact factor: 3.603

Review 6.  Dental implants in patients treated with antiresorptive medication - a systematic literature review.

Authors:  Christian Walter; Bilal Al-Nawas; Tim Wolff; Eik Schiegnitz; Knut A Grötz
Journal:  Int J Implant Dent       Date:  2016-04-04

7.  Stress response in periodontal ligament stem cells may contribute to bisphosphonate‑associated osteonecrosis of the jaw: A gene expression array analysis.

Authors:  Yueqi Shi; Mengyu Li; Yejia Yu; Yuqiong Zhou; Wenjie Zhang; Hongfei Hua; Shaoyi Wang
Journal:  Mol Med Rep       Date:  2020-06-26       Impact factor: 2.952

8.  Clinical analysis of medication related osteonecrosis of the jaws: A growing severe complication in China.

Authors:  Qizhang Wang; Jiyuan Liu; Shuqun Qi; Xuejuan Liao; Dazhong Liu; Jian Pan
Journal:  J Dent Sci       Date:  2018-02-06       Impact factor: 2.080

9.  Dentists' knowledge about osteoporosis and their ability to identify the disease.

Authors:  Renato Vicente Ferreira; Suely Roizenblatt; Vera Lucia Szejnfeld
Journal:  Adv Rheumatol       Date:  2021-08-09

10.  Oral health status of patients with multiple myeloma.

Authors:  Édila Figuerêdo Feitosa; Roberto José Pessoa Magalhães; Carlos Augusto de Melo Barbosa; Fabio Ribeiro Guedes; Angelo Maiolino; Sandra Regina Torres
Journal:  Hematol Transfus Cell Ther       Date:  2019-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.